Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16452220 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Panka DJ, Wang W, Atkins MB, Mier JW (2006) The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66, 1611-9 16452220
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S75-p - BAD (human)
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)
PD98059 decrease
U0126 decrease

S99-p - BAD (human)
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)
PD98059 no change compared to control
U0126 no change compared to control

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)
PD98059 decrease
U0126 decrease

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)
PD98059 decrease
U0126 decrease

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)
PD98059 decrease
U0126 decrease

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)
PD98059 decrease
U0126 decrease

S218-p - MEK1 (human)
Orthologous residues
MEK1 (human): S218‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)

S222-p - MEK1 (human)
Orthologous residues
MEK1 (human): S222‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)

S222-p - MEK2 (human)
Orthologous residues
MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)

S226-p - MEK2 (human)
Orthologous residues
MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A375 (melanocyte), SK-MEL5 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  A2058 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease BAY 43-9006 (sorafenib)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.